Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 1.3% - What's Next?

Key Points

• BNR stock dipped 1.3% to $20.59 on light volume (~24,167 shares, 23% below average), trading near its 200‑day SMA ($20.42) and slightly below its 50‑day SMA ($21.26).
• Analyst sentiment is mixed — Wall Street Zen upgraded to a Buy while Weiss Ratings still has a Sell (D-), and MarketBeat's consensus remains Sell; the company reported a loss of ($0.21) EPS with negative net margin (10.27%) and negative ROE (9.98%).
• Director Yusheng Han bought 314,870 shares at $17.36 (~$5.47M), raising his holdings to 17.67M shares, and insiders now own about 30.3% of the company.

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Get Free Report) was down 1.3% during trading on Thursday . The company traded as low as $20.36 and last traded at $20.59. Approximately 24,167 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 31,464 shares. The stock had previously closed at $20.86.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BNR shares. Wall Street Zen upgraded shares of Burning Rock Biotech from a "hold" rating to a "buy" rating in a report on Saturday, January 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Burning Rock Biotech in a report on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Sell".

Burning Rock Biotech Trading Down 1.3%

The firm has a market cap of $221.55 million, a PE ratio of -26.06 and a beta of 1.59. The business's 50-day simple moving average is $21.26 and its 200 day simple moving average is $20.42.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $18.05 million for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%.

Insider Buying and Selling

In other Burning Rock Biotech news, Director Yusheng Han bought 314,870 shares of the business's stock in a transaction on Tuesday, March 31st. The shares were acquired at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the transaction, the director owned 17,672,676 shares of the company's stock, valued at approximately $306,797,655.36. This trade represents a 1.81% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 30.30% of the company's stock.

Institutional Trading of Burning Rock Biotech

Several hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in Burning Rock Biotech during the 3rd quarter worth approximately $26,000. Prospera Financial Services Inc increased its holdings in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company's stock valued at $628,000 after purchasing an additional 6,430 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Burning Rock Biotech during the 4th quarter valued at approximately $220,000. Finally, Crcm LP increased its holdings in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company's stock worth $1,917,000 after acquiring an additional 26,809 shares in the last quarter. 30.03% of the stock is owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech NASDAQ: BNR is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company's core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.